Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Abbott Laboratories : $5 Covid-19 Rapid Antigen Test Gets Emergency-Use Status From FDA

08/26/2020 | 08:08pm EST

By Sarah Krouse

The U.S. Food and Drug Administration has granted emergency-use authorization to Abbott Laboratories for a $5 rapid-response Covid-19 antigen test that is roughly the size of a credit card.

The low-cost, rapid-response test could be administered in a doctor's or school nurse's office and uses technology similar to home pregnancy tests. It returns results in about 15 minutes.

The emergency approval comes as demand grows for greater access to Covid-19 diagnostic tools that deliver results in minutes, rather than days to help quickly contain infections.

Abbott said Wednesday it plans to ship tens of millions of the newly approved tests in September, with plans to increase production to 50 million tests in October. If the company is able to do so, the October total would amount to roughly double the number of tests performed in the U.S. in July.

Some public-health officials and lab executives say lower-cost rapid tests that can be produced at scale are an important factor in the country's ability to return to work and school.

Abbott's new test, called the BinaxNOW COVID-19 Ag Card, searches for virus proteins and is intended to be used for patients within seven days of feeling coronavirus symptoms. It involves a nasal swab administered by a health-care professional such as a doctor, school nurse or pharmacist. The swab is inserted into the card-like test.

The new test uses lateral flow technology that is similar to a home pregnancy test and can be linked to a mobile-phone app that gives an all-clear code, for instance, to those who test negative at work or school. The company hasn't yet determined its distribution strategy, an Abbott spokeswoman said, so it is unclear where the tests will be sent or when they will become available.

The new tests are intended to be conducted by medical professionals and aren't sold directly to consumers for at-home use.

Other rapid-response tests that have received emergency-use authorizations from the FDA run in cartridges that are analyzed by boxlike machines that can sit within doctor's offices or nursing homes. Those tests generally cost $15 to $50, though coronavirus diagnostic tests are typically free for people with symptoms or known contact with an infected individual.

The demand for rapid antigen tests and the machines that run them outstrips what their manufacturers are able to produce.

Abbott said its data show the new antigen test has demonstrated sensitivity -- the percent of positive cases a test accurately detects -- of about 97%. Rapid antigen tests are generally thought to be less sensitive than lab-based PCR tests.

The company earlier this year began investing in two U.S. production facilities to produce large numbers of the new tests, said John Hackett, divisional vice president of applied research and technology for Abbott's diagnostics unit.

"It's frankly what the country needs right now," said Dr. Hackett. "The drive behind this from day one has been to get people back to work, back to school," he added.

The company makes several other types of coronavirus tests including a rapid molecular test used by the White House that delivers results in under 15 minutes. The company revised instructions for use of that rapid test after a preliminary study by a major medical center found that it frequently gave false negative results.

Many states raced to secure those tests, with some frustrated over how long it took to have orders filled. The federal government has purchased large numbers of rapid-response Covid-19 tests through the pandemic and typically gets priority distribution.

Write to Sarah Krouse at sarah.krouse@wsj.com

 

Stocks mentioned in the article
ChangeLast1st jan.
ABBOTT LABORATORIES -0.31% 108.15 Delayed Quote.24.51%
THE HACKETT GROUP, INC. 2.18% 14.5 Delayed Quote.-12.08%
All news about ABBOTT LABORATORIES
12/02ABBOTT LABORATORIES : FreeStyle Libre 2 Now Approved for Adults and Children wit..
AQ
11/20ABBOTT LABORATORIES : Change in Directors or Principal Officers (form 8-K)
AQ
11/19ABBOTT LABORATORIES : Becomes first anchor sponsor of american diabetes associat..
AQ
11/18ABBOTT LABORATORIES : Launches the first infant formula in canada with an ingred..
AQ
11/17ABBOTT LABORATORIES : Launches the First Infant Formula in Canada with an Ingred..
AQ
11/17ABBOTT LABORATORIES : Named industry sustainability leader for the eighth year i..
AQ
11/16HHS Official Says The Agency Has Responded To Every State That Has Requested ..
RE
11/16ABBOTT : Named Industry Sustainability Leader for the Eighth Year in a Row on th..
PR
11/12ABBOTT LABORATORIES : Entry into a Material Definitive Agreement, Termination of..
AQ
11/12ABBVIE : Vice Chairman, Chief Commercial Officer Carlos Alban to Retire
DJ
More news
Financials (USD)
Sales 2020 33 873 M - -
Net income 2020 4 415 M - -
Net Debt 2020 11 794 M - -
P/E ratio 2020 44,1x
Yield 2020 1,33%
Capitalization 192 B 192 B -
EV / Sales 2020 6,01x
EV / Sales 2021 5,23x
Nbr of Employees 107 000
Free-Float 88,9%
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 118,44 $
Last Close Price 108,15 $
Spread / Highest target 20,2%
Spread / Average Target 9,52%
Spread / Lowest Target -24,2%
EPS Revisions
Managers
NameTitle
Robert B. Ford President, CEO, Chief Operating Officer & Director
Miles D. White Executive Chairman
Robert E. Funck Chief Financial Officer & Executive Vice President
Roxanne Schuh Austin Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES24.51%191 681
MEDTRONIC PLC0.13%152 346
BECTON, DICKINSON AND COMPANY-11.07%70 150
HOYA CORPORATION30.14%48 552
ALIGN TECHNOLOGY, INC.81.15%39 857
BAXTER INTERNATIONAL INC.-8.69%39 001